Pharma Journalist 8969 posts 0 comments

As investment, innovation, and dealmaking continue to reshape the antibody-drug conjugate (ADC) landscape, Michael Torres, Chief Executive Officer of CrossBridge Bio, has shared his…
Read More...

Are We Asking the Right Questions in COPD Drug Development? As the industry looks beyond traditional measures such as lung function and exacerbations, a new question is emerging: What…
Read More...

argenx has agreed to acquire Forte Biosciences for approximately $2.2 billion in cash, strengthening its immunology pipeline with a promising experimental therapy for autoimmune…
Read More...

BioMarin Pharmaceutical and the n-Lorem Foundation have entered a strategic collaboration to develop what could become the first disease-modifying treatment for ReNU syndrome, a rare…
Read More...

Pfizer Japan Inc. and Eisai Co., Ltd. have announced a new collaboration to co-promote the migraine treatment Nurtec OD Tablet 75mg (rimegepant sulfate hydrate) across Japan beginning…
Read More...

Biointron Biological USA Inc. has introduced RushData, a new integrated service platform designed to accelerate antibody discovery by providing rapid experimental validation for…
Read More...

Outlook Therapeutics has secured U.S. Food and Drug Administration (FDA) approval for LYTENAVA™ (bevacizumab-vikg), making it the first and only FDA-approved ophthalmic formulation of…
Read More...

Bora Pharmaceuticals and South Korea-based Onconic Therapeutics have entered into a manufacturing agreement to support the U.S. clinical development of JAQBO, an investigational…
Read More...

Lundbeck has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Lu AH69593, its investigational oral orexin 2 receptor agonist being developed to treat…
Read More...

Affinia Therapeutics has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for its investigational gene therapy AFTX-201, marking another regulatory…
Read More...